Effect of Nicardipine Treatment on Carbohydrate and Lipoprotein Metabolism in Patients with Hypertension

References

• Veterans Administration Cooperative Study Group on Antihypertensive Agents. Effects of treatment on morbidity in hypertension II. Results in patients with diastolic blood pressure averaging 90 through 114 mmHg. JAMA 1970; 213: 1143–52
   PubMed Web of Science ®Google Scholar
• Hypertension Detection and Follow-up Program Cooperative Group. Five-year findings of the hypertension detection and follow-up program: I. Reduction in mortality of persons with high blood pressure, including mild hypertension. JAMA 1979; 242: 2562–71
   PubMed Web of Science ®Google Scholar
• Multiple Risk Factor Intervention Trial Research Group. Multiple risk factor intervention trial: Risk factor changes and mortality results. JAMA 1982; 248: 1465–77
   PubMed Web of Science ®Google Scholar
• The Management Committee of the Australian Therapeutic Tiral in Mild Hypertension. Untreated mild hypertension. A report by the Managment Committee of the Australian Therapeutic Trial in mild hypertension. Lancet 1982; I: 185–91
   Google Scholar
• Weinberger M H. Antihypertensive therapy and lipids: paradoxical influences on cardiovascular disease risk. Am J Med 1986; 80(suppl 2A)64–70
   PubMed Web of Science ®Google Scholar
• Lardinois C K, Neuman S L. The effects of antihypertensive agents on serum lipids and lipoproteins. Arch Intern Med 1988; 148: 1280–8
   PubMed Web of Science ®Google Scholar
• Shen D-C, Shieh S-M, Fuh M M-T, Wu D-A, Chen Y-D I, Reaven G M. Resistance to insulin-stimulated-glucose uptake in patients with hypertension. J Clin Endocrinol Metab 1988; 66: 580–3
   PubMed Web of Science ®Google Scholar
• Ferrannini E, Buzzigoli G, Bonadona R, et al. Insulin resistance in essential hypertension. N Engl J Med 1987; 317: 350–7
   PubMed Web of Science ®Google Scholar
• Swislocki A LM, Hoffman B B, Reaven G M. Insulin resistance, glucose intolerance and hyperinsulinemia in patients with hypertenson. Am J Hypertens 1989; 2: 419–23
   PubMed Web of Science ®Google Scholar
• Pyorala K, Savolainen E, Lehtovirta E, Punsar S, Siltanen P. Glucose tolerance and coronary artery disease: Helsinki Policemen Study. J Chron Dis 1979; 32: 729–45
   PubMedGoogle Scholar
• Welborn T A, Wearne K. Coronary heart disease incidence and cardiovascular mortality in Busselton with reference to glucose and insulin concentration. Diabetes Care 1979; 2: 154–60
   PubMedGoogle Scholar
• Ducimetiere P, Eschwege E, Papoz L, Richard J L, Claud J R, Rosselin G. Relationship of plasma insulin levels to the incidence of myocardial infarction and coronary artery disease mortality in a middle-aged population. Diabetologia 1980; 19: 205–10
   PubMed Web of Science ®Google Scholar
• Fuh M M-T, Shieh S-M, Wu D-A, Chen Y-D I, Reaven G M. Abnormalities of carbohydrate and lipid metabolism in patients with hypertension. Arch Intern Med 1987; 147: 1035–8
   PubMed Web of Science ®Google Scholar
• Pepine C J, Lambert C R. Usefulness of nicardipine for angina pectoris. Am J Cardiol 1987; 59: 13J–19J
   PubMed Web of Science ®Google Scholar
• Ram C VS. Nicardipine for systolic hypertension: Effects on blood pressure and target organ function. Am J Cardiol 1987; 59: 25J–30J
   PubMed Web of Science ®Google Scholar
• Semple C G, Thomson J A, Beastall G H, Lovimer A R. Oral verapamil does not affect glucose tolerance in non-diabetics. Br J Clin Pharmac 1983; 15: 570–1
   PubMed Web of Science ®Google Scholar
• Vessby B, Aberlin J, Finnon M, Hellsing K, Lithell H. Effects of nifedipine treatment on carbohydrate and lipoprotein metabolism. Current Therapeutic Res 1983; 33: 1075–80
   Web of Science ®Google Scholar
• Charles S, Ketelslegers J M, Buysschaert M, Lambert A E. Hyperglycemic effect of nifedinpine. Br Med J 1981; 283: 19–20
   PubMed Web of Science ®Google Scholar
• Giugliano D, Torella R, Cacciapuoti F, Gentile S, Verza M, Varricchio M. Impairment of insulin secretion in man by nifedipine. Eur J Clin Pharmac 1980; 18: 395–8
   PubMed Web of Science ®Google Scholar
• Grodsky G M, Bennett L L. Cation requirements for insulin secretion in the isolated perfused pancreas. Diabetes 1966; 15: 910–3
   PubMed Web of Science ®Google Scholar
• Hellman B. The significance of calcium for glucose stimulation of insulin release. Endocrinol 1975; 97: 392–8
   PubMed Web of Science ®Google Scholar
• Levy J, Herchulz A, Sener A, Malaisse W J. Inhibition by verapamil of calcium influx in the beta-cell. Diabetes 1985; 34(Suppl 2)400
   Google Scholar
• Fuh M M-T, Sheu W H-H, Shen D-C, Wu D-A, Chen Y-D I, Reaven G M. Metabolic effects of diuretic and beta-blocker treatment of hypertension in patients with NIDDM. Am J Hypertens 1990; 3: 387–90
   PubMed Web of Science ®Google Scholar
• Pollare T, Lithell H, Selinus I, Berne C. Application of prazosin is associated with an increase of insulin sensitivity in obese patients with hypertension. Diabetologia 1988; 31: 415–20
   PubMed Web of Science ®Google Scholar
• Swislocki A LM, Hoffman B B, Sheu W H-H, Chen Y-D I, Reaven G M. Effect of prazosin treatment on carbohydrate and lipoprotein metabolism in patients with hypertension. Am J Med 1989; 86(Suppl 1B)14–8
   PubMed Web of Science ®Google Scholar
• Kadish A H, Litle R L, Sternberg J C. A new and rapid method for the determination of glucose by measurement of rate of oxygen consumption. Clin Chem 1968; 14: 116–31
   Web of Science ®Google Scholar
• Hales C N, Randle P J. Immunoassay of insulin with insulin-antibody precipitate. Biochem J 1963; 88: 137–46
   PubMed Web of Science ®Google Scholar
• Bonser A, Garcia-Webb P. C-peptide measurements: methods and clinical utility. CRC Critical Review in Laboratory 1984; 19: 297–352
   Web of Science ®Google Scholar
• Ross I S, Michell A F, Stroud R E. Glycosylated hemoglobin and glycosylated plasma protein. A comparative study. Clin Chem Acta 1986; 156: 319–26
   Google Scholar
• Wahlefeld A W. Triglyceride. Determination after enzymatic hydrolysis. Methods of enzymatic analysis, H V Bergmeryer. Academic PRess, New York 1974; 1831–6
   Google Scholar
• Allain C C, Poon L S, Chan C SG, et al. Enzymatic determination of total serum cholesterol. Clin Chem 1975; 20: 470–5
   Web of Science ®Google Scholar
• Golay A, Zech L, Shi M-Z, Chiou Y-A M, Reaven G M, Chen Y-D I. High density lipoprotein metabolism in non-insulin-dependent diabetes mellitus: measurements of HDL turnover using tritiated HDL. J Clin Endcrinol Metab 1987; 65: 512–8
   PubMed Web of Science ®Google Scholar
• Reaven G M, Miller R. Study of the relationship between glucose and insulin responses to an oral glucose load in man. Diabetes 1968; 17: 560–9
   PubMed Web of Science ®Google Scholar
• Polonsky K S, Rubenstein A H. C-peptide measurement of the secretion and hepatic extraction of insulin. Pitfalls and limitation. Diabetes 1984; 33: 486–93
   PubMed Web of Science ®Google Scholar
• Asplund J. Nicardipine hydrochloride in essential hypertension — a controlled study. Br J Clin Pharmac 1985; 20: 120S–4S
   PubMed Web of Science ®Google Scholar
• Dow R J, Baty J, Isles T E. The effect of nicardipine on glucose and drug-stimulated insulin secretion in normal volunteers. Br J Clin Pharmac 1985; 20: 75S–83S
   PubMed Web of Science ®Google Scholar
• Kagome K, Matsumura S, Yaga K, et al. Clinical usefullness of nicardipine HCl in diabetes with hypertension. J Adult Dis 1985; 15: 235–8
   Google Scholar
• Yajima Y, Sakai H, Takei Y, Nakamura H, Tsuyusaki T, Matoba K. Effects of administration of calcium antagonist nicardipine HCl on glucose tolerance and IRI secretion in diabetics with hypertension as a complication. Med Consult New Remedies 1984; 21: 1133–40
   Google Scholar
• Kihara A. Effect of the calcium antagonist nicardipine hydrochloride on glucose tolerance and insulin secretion. Am Heart J 1991; 122: 363–9
   PubMed Web of Science ®Google Scholar
• DeMarinis L, Barbarino A. Calcium antagonists and hormone release I. Effects of verapamil on insulin release in normal subjects and patients with islet-cell tumor. Metabolism 1980; 29: 599–604
   PubMed Web of Science ®Google Scholar
• Berne C, Pollare T, Lithell H. Effect on antihypertensive treatment on insulin sensitivity with special reference to ACE inhibitor. Diabetes Care 1991; 14(Suppl. 4)39–47
   PubMed Web of Science ®Google Scholar
• Pollare T, Lithell H, Morlin C, Prantare H, Hvarfner A, Ljunghall S. Metabolic effects of diltiazem and atenolol: results from a randomised, double blind study with parallel group. J Hypertens 1989; 7: 551–9
   PubMed Web of Science ®Google Scholar
• Sheu W H-H, Swislocki A LM, Hoffman B B, Chen Y-D I, Reaven G M. Comparison of the effects of atenolol and nifedipine on glucose, insulin and lipid metabolism in patients with hypertension. Am J Hypertens 1991; 4: 199–205
   PubMed Web of Science ®Google Scholar
• Bahtnagar S K, Amin M MA, A-Yusuf A R. Diabetogenic effect of nifedipine. Br Med J 1984; 289: 19
   Web of Science ®Google Scholar
• Giuntoli F, Scalabrino A, Pagliai E, et al. Antihypertensive and metabolic effect of long-term treatment with nifedipine. Clin Trial J 1985; 22: 231–8
   Google Scholar
• Landmark K. Antihypertensive and metabolic effects of long-term therapy with nifedipine slow-release tablets. J Cardiovasc Pharmac 1985; 7: 12–7
   PubMed Web of Science ®Google Scholar
• Benaim M E, MacDonald G. Effect of nifedipine on carbohydrate metabolism and serum lipoproteins in hypertensive patients with and without diabetes mellitus. Eur Heart J 1987; 8(Suppl K)15–20
   PubMedGoogle Scholar
• Ohata J, Sakamoto N, Nagano K, Maeno H. Low density lipoprotein-lowering and high density lipoprotein elevating effects of nicardipine in rats. Biochem Pharma 1984; 33: 2199–2205
   PubMed Web of Science ®Google Scholar